Alpha 2.0
Login Register
» Authors » Masahiko Tsuboi

Masahiko Tsuboi

Explore the profile of Masahiko Tsuboi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 17
Followers 0
Related Specialties
Rheumatology
Allergy & Immunology
Top 10 Co-Authors
Atsushi Kawakami
Shin-Ya Kawashiri
Tomohiro Koga
Naoki Matsuoka
Toshimasa Shimizu
Mami Tamai
Shuntaro Sato
Tomoki Origuchi
Keita Fujikawa
Yoshiro Horai
Published In
Int J Rheum Dis
Arthritis Res Ther
Drug Discov Ther
Case Rep Rheumatol
Rheumatology (Oxford)
Affiliations
Soon will be listed here.
Recent Articles
1.
Efficacy of etanercept biosimilar switching from etanercept reference product, using ultrasound and clinical data in outcomes of real world therapy (ESCORT-NGSK Study)
Sumiyoshi R, Kawashiri S, Shimizu T, Koga T, Kiya R, Tashiro S, et al.
Drug Discov Ther . 2025 Feb; 19(1):29-37. PMID: 40010737
This study aimed to investigate in detail the efficacy of switching from etanercept reference product (RP) to etanercept biosimilar in patients with rheumatoid arthritis (RA) under real-world clinical conditions using...
2.
Successful treatment of systemic lupus erythematosus with residual disease activity by switching from belimumab to anifrolumab
Umeda M, Kojima K, Michitsuji T, Tsuji Y, Shimizu T, Fukui S, et al.
Mod Rheumatol . 2024 May; 34(6):1281-1283. PMID: 38756072
No abstract available.
3.
Life prognosis and renal relapse after induction therapy in Japanese patients with proliferative and pure membranous lupus nephritis
Okamoto M, Kitamura M, Sato S, Fujikawa K, Horai Y, Matsuoka N, et al.
Rheumatology (Oxford) . 2020 Nov; 60(5):2333-2341. PMID: 33166998
Objective: We aimed to compare life prognosis and renal relapse after induction therapy in proliferative (PLN) and pure membranous LN (MLN). Methods: We retrospectively analysed the cases of 140 of...
4.
Comparison of complete renal response and mortality in early- and late-onset lupus nephritis: a multicenter retrospective study of a Japanese cohort
Ichinose K, Kitamura M, Sato S, Fujikawa K, Horai Y, Matsuoka N, et al.
Arthritis Res Ther . 2020 Jul; 22(1):175. PMID: 32698892
Background: Most patients with systemic lupus erythematosus (SLE) progress to lupus nephritis (LN) within 5 years of their SLE diagnosis, although it is not uncommon for LN to develop at...
5.
Podocyte foot process width is a prediction marker for complete renal response at 6 and 12 months after induction therapy in lupus nephritis
Ichinose K, Kitamura M, Sato S, Fujikawa K, Horai Y, Matsuoka N, et al.
Clin Immunol . 2018 Oct; 197:161-168. PMID: 30296591
Morphological change that includes diffuse effacement of podocyte foot processes is correlated with proteinuria in patients with lupus nephritis (LN). We collected the data of clinico-pathological parameters and assessed foot...
6.
Effectiveness of Certolizumab Pegol in Treating Rheumatoid Arthritis Patients with Persistent Inflamed Residual Mono- or Oligosynovitis Resistant to Prior TNF-α Inhibitors
Koarada S, Tsuboi M, Komine M, Nakao Y, Tokuda Y, Ono Y, et al.
Case Rep Rheumatol . 2015 Oct; 2015:348614. PMID: 26451269
We report four cases of successful treatment with certolizumab pegol (CZP) of rheumatoid arthritis (RA) patients with persistent inflamed residual mono- or oligosynovitis resistant to prior TNF-α inhibitors. Although the...
7.
Two elderly cases of familial mediterranean fever with rheumatoid arthritis
Matsuoka N, Iwanaga J, Ichinose Y, Fujiyama K, Tsuboi M, Kawakami A, et al.
Int J Rheum Dis . 2014 Mar; 21(10):1873-1877. PMID: 24661635
Familial Mediterranean fever (FMF) is a genetic autoinflammatory disorder that usually develops before 20 years of age and is characterized by periodic fever with serositis and arthritis. Both FMF and...